目的 研究黃芪注射液聯(lián)合他克莫司對原發(fā)性腎病綜合征患者的治療效果及對血液黏稠狀態(tài)的影響。方法 選擇2015年1月—2017年10月在西安濟仁醫(yī)院診治的59例原發(fā)性腎病綜合征患者，隨機分為對照組30例和觀察組29例。對照組口服他克莫司膠囊治療，初始劑量為每天0.1 mg/kg，每天2次，與早餐和晚餐前1 h口服，連續(xù)給藥6個月；觀察組聯(lián)合靜脈滴注黃芪注射液治療，把40 mL的黃芪注射液溶于250 mL的10%葡萄糖溶液中進行靜脈滴注，每天給藥1次。兩組均連續(xù)治療6個月。比較兩組的臨床治療效果、血黏稠度和血小板聚集率，比較兩組治療前后的CD4⁺、CD3⁺、CD8⁺以及CD4⁺/CD8⁺等細胞免疫功能指標和血清白介素-6、腫瘤壞死因子-α以及白介素-23水平。結(jié)果 觀察組的有效率72.41%明顯高于對照組43.33%，差異有統(tǒng)計學(xué)意義（P<0.05）。治療后兩組的血小板聚集率和血黏稠度均明顯降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且觀察組明顯低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。兩組治療后的CD4⁺、CD3⁺以及CD4⁺/CD8⁺均升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且觀察組明顯高于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。兩組治療后的白介素-6、腫瘤壞死因子-α以及白介素-23水平均降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且觀察組明顯低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 黃芪注射液與他克莫司聯(lián)合使用可以顯著提高原發(fā)性腎病綜合征患者的治療效果，降低血液高黏狀態(tài)，控制炎癥反應(yīng)，增強免疫功能，值得應(yīng)用推廣。

Objective To investigate the clinical effect of astragalus injection combined with tacrolimus on blood viscosity in patients with primary nephrotic syndrome.Methods Fifty-nine patients with primary nephrotic syndrome who were treated in our hospital from January 2015 to October 2017 were randomly divided into 30 control groups and 29 observation groups. The control group was treated with Tacrolimus Capsules, and the observation group was treated with intravenous drip of Astragalus injection. The clinical effects of the two groups were compared.Results After treatment, the effective rate of the observation group was 72.41%, which was significantly higher than the control group of 43.33% (P<0.05); the platelet aggregation rate and blood viscosity of the two groups were significantly decreased, and the decrease in the observation group was more obvious (P<0.05); CD4⁺, CD3⁺ and CD4⁺/CD8⁺ in two groups were significantly increased, and the observation group was more obvious (P<0.05); the levels of interleukin - 6, tumor necrosis factor alpha and interleukin -23 in the two groups were significantly decreased, and the observation group was more obvious (P<0.05). Conclusion The combination of Astragalus injection and tacrolimus can significantly improve the therapeutic effect of primary nephrotic syndrome, reduce the blood viscosity, control inflammatory reaction and enhance the immune function, which is worthy of application.